166 related articles for article (PubMed ID: 10843211)
1. Structure-activity relationship studies of flavopiridol analogues.
Murthi KK; Dubay M; McClure C; Brizuela L; Boisclair MD; Worland PJ; Mansuri MM; Pal K
Bioorg Med Chem Lett; 2000 May; 10(10):1037-41. PubMed ID: 10843211
[TBL] [Abstract][Full Text] [Related]
2. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
[TBL] [Abstract][Full Text] [Related]
3. [Flavopiridol, a cyclin-dependent kinase inhibitor].
Lansiaux A; Bailly C
Bull Cancer; 2000 Oct; 87(10):697-701. PubMed ID: 11084532
[No Abstract] [Full Text] [Related]
4. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
De Azevedo WF; Mueller-Dieckmann HJ; Schulze-Gahmen U; Worland PJ; Sausville E; Kim SH
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2735-40. PubMed ID: 8610110
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
8. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase.
Kaiser A; Nishi K; Gorin FA; Walsh DA; Bradbury EM; Schnier JB
Arch Biochem Biophys; 2001 Feb; 386(2):179-87. PubMed ID: 11368340
[TBL] [Abstract][Full Text] [Related]
9. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.
Schoepfer J; Fretz H; Chaudhuri B; Muller L; Seeber E; Meijer L; Lozach O; Vangrevelinghe E; Furet P
J Med Chem; 2002 Apr; 45(9):1741-7. PubMed ID: 11960485
[TBL] [Abstract][Full Text] [Related]
13. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA
Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.
Sausville EA
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):47-56. PubMed ID: 12678914
[TBL] [Abstract][Full Text] [Related]
15. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.
Wang LM; Ren DM
Mini Rev Med Chem; 2010 Oct; 10(11):1058-70. PubMed ID: 21047304
[TBL] [Abstract][Full Text] [Related]
16. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
Shapiro GI; Koestner DA; Matranga CB; Rollins BJ
Clin Cancer Res; 1999 Oct; 5(10):2925-38. PubMed ID: 10537362
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol binds to duplex DNA.
Bible KC; Bible RH; Kottke TJ; Svingen PA; Xu K; Pang YP; Hajdu E; Kaufmann SH
Cancer Res; 2000 May; 60(9):2419-28. PubMed ID: 10811119
[TBL] [Abstract][Full Text] [Related]
18. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
20. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol.
Tsitsanou KE; Hayes JM; Keramioti M; Mamais M; Oikonomakos NG; Kato A; Leonidas DD; Zographos SE
Food Chem Toxicol; 2013 Nov; 61():14-27. PubMed ID: 23279842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]